top of page
surf break copy_edited.jpg

Iterative Scopes brings gastrointestinal disease AI to Janssen's IBD clinical trials

Updated: Jan 27, 2022

By: Andrea Park

After chipping into its last two venture funding rounds, Johnson & Johnson is taking an even bigger chance on Iterative Scopes. The startup, which spun out of MIT in 2017, is developing artificial intelligence tools to both improve screenings for gastrointestinal diseases like colorectal cancer and inflammatory bowel disease (IBD) and boost the entire clinical trial process, including accelerating patient recruitment and improving endpoint selection. Now, J&J’s Janssen R&D division will tap those AI technologies, teaming up with Iterative Scopes to improve its own clinical trials for treatments of IBD.

Recent Posts

See All


bottom of page